Answers are grounded in this paper and cite their sources.
To complete the review article by Abes and colleagues (Pharmaceuticals 2010, 3, 146-157) which provides a good overview on recently developed approaches for generation of glyco-modified antibodies and the impact of glyco-modification of antibodies on their effector functions, important information should be added, namely that - besides the Glycart and the Biowa approach to generate de-fucosylated antibodies - innovative, moss derived methods have been shown to generate glyco-modified antibodies with improved effector function profile.
No takes yet. Share an insight, caveat, or question.
Nechansky et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: